

Zara, J.
09/684061

09/684061

FILE 'REGISTRY' ENTERED AT 11:49:37 ON 01 NOV 2004

L1 7 S GCTCTTCATGAACAGCAGAAG/SQSN
L2 2 S L1 AND SQL=<100

FILE 'CAPLUS' ENTERED AT 11:53:21 ON 01 NOV 2004

L3 1 S L2

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 13 Apr 2001

ACCESSION NUMBER: 2001:265584 CAPLUS

DOCUMENT NUMBER: 134:294085

TITLE: Hematopoietic stem cells (HSC) treated with antisense oligonucleotide targeted to genes preferentially expressed in HSC and cancer treatment

INVENTOR(S): Bartelmez, Stephen H.; Iversen, Patrick L.

PATENT ASSIGNEE(S): Avi Biopharma, Inc., USA

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025422	A2	20010412	WO 2000-US27636	20001006
W: AU, CA, JP, KR				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1228202	A2	20020807	EP 2000-968807	20001006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2003511393	T2	20030325	JP 2001-528575	20001006
PRIORITY APPLN. INFO.:			US 1999-158340P	P 19991007
			WO 2000-US27636	W 20001006

AB The present invention relates to the preparation of hematopoietic stem cells (HSC) treated with antisense oligonucleotide targeted to genes preferentially expressed in HSC which can be used in cancer treatment. A composition comprising an antisense oligomer directed to an mRNA

preferentially expressed in stem cells is described together with methods for treating stem cells with such a composition to increase the number of lineage committed

progenitor cells and their progeny, and/or slow the growth of cancer cells. These antisense oligonucleotides contain repeating morpholino subunits having 5-atom (A), six-atom (B) and seven-atom (C-E) linking groups suitable for forming polymers which are resistant to nuclease. The HSC genes include EVI-1 zinc finger gene, serum-14 deprivation response gene, multimerin gene, tissue transglutaminase gene, FE65 gene, RAB27 gene, Jagged2 gene, c-myc gene, Notch I gene, Notch2 gene and Notch3 gene. Also described is the use of such compns. and antisense oligonucleotide-treated stem cells as a medicament.

IT 334072-34-3P

RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antisense oligonucleotide targeted to HSC preferential genes;

09/684061

hematopoietic stem cells (HSC) treated with antisense oligonucleotide targeted to genes preferentially expressed in HSC and cancer treatment)

E1 THROUGH E1 ASSIGNED

FILE 'REGISTRY' ENTERED AT 11:53:48 ON 01 NOV 2004

L4 1 S E1

L5 1 L1 AND L4

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 334072-34-3 REGISTRY

CN DNA, d(G-C-T-C-T-C-A-T-G-A-A-C-A-G-C-A-G-A-A-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1: PN: WO0125422 SEQID: 1 claimed DNA

CI MAN

SQL 21

SEQ 1 gctcttcatg aacagcagaa g
===== ===== =

HITS AT: 1-21

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 134:294085

(FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 11:54:13 ON 01 NOV 2004)

L6 0 S L2

FILE 'HOME' ENTERED AT 11:54:37 ON 01 NOV 2004